Market Overview

Biocept Could Double On Liquid Biopsy Leadership: H.C. Wainwright

Biocept Could Double On Liquid Biopsy Leadership: H.C. Wainwright

In illiquid pre-market trading, Biocept Inc (NASDAQ: BIOC) was indicated 6 percent higher at $2.08 following a bullish note from H.C. Wainwright & Co. analyst Yi Chen.

Chen, who has a Ph.D. in biochemistry, is optimistic on Biocept's liquid biopsy technology, which he said provides a "less invasive and less expensive" way to test for biomarkers in breast, lung, gastric and colorectal cancers. Further, the company plans to launch testing for additional biomarkers, Chen pointed out.

In addition, Chen argued that Biocept management is executing, highlighting collaboration with research institutions.

"Since Biocept has recently launched multiple tests targeting multiple cancer sites, we expect sales from commercial cases to continue to ramp up quickly," he said. In the liquid biopsy market, Chen predicted that the company has the "most advanced technology" and can offer the "most tests in terms of cancer sites and biomarkers."

Against this backdrop, Chen said that the shares as of Tuesday's close were undervalued by half, particularly "given that its cancer tests have been generating commercial sales and have considerable market potential." The $4 price target will give Biocept a market capitalization of $98 million.

Shares are quite volatile, with prices in February trading from below $1.20 to above $4.75 within a few days. As of Tuesday's $1.96 closing price, the stock has shed 21 percent year-to-date. Most recently, shares have slid from $3.30 in June to below $2 at present.

Latest Ratings for BIOC

Mar 2019Maxim GroupInitiates Coverage OnBuy
Jun 2017Chardan CapitalInitiates Coverage OnBuy
Nov 2016Feltl & Co.UpgradesHoldBuy

View More Analyst Ratings for BIOC
View the Latest Analyst Ratings


Related Articles (BIOC)

View Comments and Join the Discussion!

Posted-In: Biocept H.C. Wainwright & Co. yi chenAnalyst Color Biotech Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

COREBMO CapitalUpgrades40.0
KINAegis CapitalMaintains16.0
SBNYCredit SuisseMaintains180.0
NFECredit SuisseMaintains50.0
SLBCredit SuisseMaintains25.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at